HOME >> BIOLOGY >> NEWS
What does an airline traveler have in common with a glowing fish?

In William Gibson's novel Pattern Recognition, the protagonist posits a theory of jet lag: "Souls can't move that quickly, and are left behind, and must be awaited, upon arrival, like lost luggage." Science has yet to address the issue of a spiritual speed limit, but it is generally accepted that jet lag actually results from the upset of the body's circadian clock, a biochemical pacemaker that dictates daily rhythms in sleep and wakefulness as well as body temperature and metabolic activity.

Circadian rhythms are regulated by changes in daylight cycles, but how and when they first develop is not well understood. Reported this week in the open-access journal PLoS Biology, Maki Kaneko and Gregory Cahill have created a new tool for investigating the components of the circadian clock in vertebrates: a zebrafish that luminesces (glows) in sync with the periodicity of its circadian clock. They find, contrary to earlier studies, that aspects of circadian rhythms are not hardwired into the embryo, but develop in specific stages.

To do this, the researchers created a transgene that places expression of the firefly luciferase gene under the control of the promoter of the zebrafish circadian gene period3 (per3). Each cell of the transgenic fish has one normal copy of the per3 gene and one copy of the period3-luciferase fusion gene (per3-luc). Therefore, whenever per3 expression is normally turned on in a cell, the cell produces Per3 protein and also produces the luciferase protein.

Kaneko and Cahill anticipate that these transgenic zebrafish will be quite useful in examining the molecular machinery of the vertebrate circadian clock. For example, researchers can use the per3-luc transgenic zebrafish in forward genetic screens to identify new molecular regulators of circadian rhythms. What is more, luminescence can be measured quickly and noninvasively, making this animal an ideal candidate for high-throughput screening aimed at iden
'"/>

Contact: Paul Ocampo
pocampo@plos.org
1-415-624-1224
Public Library of Science
31-Jan-2005


Page: 1 2

Related biology news :

1. Genetic fellow traveler discovered in Alzheimers
2. Manatee traveler in northeastern waters not Chessie
3. Study finds medication prevents travelers diarrhea
4. Norovirus found to cause travelers diarrhea
5. Features of replication suggest viruses have common themes, vulnerabilities
6. Risk of common vaginal infection linked to preterm birth appears higher for blacks
7. New gene mutation identified in common type of dementia
8. Study identifies a common genetic risk factor for colorectal and prostate cancer
9. Researchers pit novel version of common virus against cancer
10. Gene responsible for common hearing loss identified for first time
11. OSA symptoms more common among African-American women than Caucasians

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: What does airline traveler have common with glowing fish

(Date:10/17/2014)... – Accurate knowledge regarding Ebola is critical and pertinent ... of hazardous global outbreak and epidemic. The Journal, ... a special issue, Ebola Virus and Public Health, to ... knowledge in this critical societal moment. , On ... Ebola for Clinicians . The primer was prepared by ...
(Date:10/17/2014)... This news release is available in German . ... for only a very few drugs. When treating overdoses, doctors ... Treatment is especially difficult if there is a combination of ... is playing and accidentally swallows his grandmother,s pills? ETH professor ... Zurich wanted to find an answer to this question. "The ...
(Date:10/16/2014)... managers have a new synthesis of recent research findings ... forests in the two states. , The Ecology ... and Washington: A Synthesis of the Relevant Biophysical Science ... report published by the U.S. Forest Service,s Pacific Northwest ... from managers for a synthesis of the large body ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3New report synthesizes best available science on management of moist mixed-conifer forests 2
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
(Date:10/20/2014)...  GenVec, Inc. (NASDAQ: GNVC ) today announced ... its board of directors effective on October 24, 2014.   Dr. ... as its chairman from June 2006 to November 2013.  During ... Governance and Audit Committees of the board.  ... dedicated service to GenVec, and its stockholders," said Wayne ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2
Cached News: